Skip to main content

Melanoma Clinical Trials

Review the melanoma clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 275

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Status: Active
Location: 661 locations
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients with Cancer That Has Spread to the Brain
Status: Active
Location: 225 locations
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients with Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Status: Active
Location: 201 locations
Using Nivolumab Alone or with Cabozantinib to Prevent Mucosal Melanoma Return after Surgery
Status: Active
Location: 139 locations
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Status: Active
Location: 27 locations
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Status: Active
Location: 27 locations
Immunotherapy in Combination with Prednisone and Sirolimus for Kidney Transplant Recipients with Unresectable or Metastatic Skin Cancer
Status: Active
Location: 25 locations
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Status: Active
Location: 20 locations
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Status: Active
Location: 20 locations
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Status: Active
Location: 19 locations
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Status: Active
Location: 17 locations
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Status: Active
Location: 15 locations
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Status: Active
Location: 15 locations
STK-012 Monotherapy and in Combination Therapy in Patients With Solid Tumors
Status: Active
Location: 15 locations
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Status: Active
Location: 16 locations
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
Status: Active
Location: 12 locations
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Status: Active
Location: 11 locations
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma that has Progressed on the Usual Treatment
Status: Active
Location: 12 locations
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Status: Active
Location: 11 locations
A Study of NX-1607 in Adults With Advanced Malignancies
Status: Active
Location: 10 locations
IO102/IO103 and Nivolumab-Relatlimab Fixed Dose Combination for the Treatment of Patients with Untreated, Unresectable Stage III/IV Melanoma
Status: Active
Location: 9 locations
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Status: Active
Location: 9 locations
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Status: Active
Location: 9 locations
Immunotherapy (Tebentafusp) and Radiation Therapy (Yttrium-90 Radioembolization) for the Treatment of Uveal Melanoma Metastatic to the Liver
Status: Active
Location: 8 locations
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Active
Location: 8 locations